- Research Tracker
- Supplement safety
- Folate and folic acid
What public sources say about the safety of folate and folic acid: FDA adverse-event reports, NIH guidance on interactions with medicines, and the registered trials that test it.
Interactions and safety, in NIH's words
Folate supplements can interact with several medications. A few examples are provided below. Individuals taking these medications on a regular basis should discuss their folate intakes with their health care providers.
Methotrexate (Rheumatrex, Trexall), used to treat cancer and autoimmune diseases, is a folate antagonist. Patients taking methotrexate for cancer should consult their oncologist before taking folate supplements because the supplements could interfere with methotrexate’s anticancer effects [166]. However, folate supplements might reduce the gastrointestinal side effects of low-dose methotrexate taken for rheumatoid arthritis or psoriasis [167,168].
Antiepileptic medications, such as phenytoin (Dilantin), carbamazepine (Carbatrol, Tegretol, Equetro, Epitol), and valproate (Depacon), are used to treat epilepsy, psychiatric diseases, and other medical conditions. These medications can reduce serum folate levels [169]. Furthermore, folate supplements might reduce serum levels of these medications, so patients taking antiepileptic drugs should check with their health care provider before taking folate supplements [166].
Medicines covered in that section: Methotrexate, Antiepileptic medications, Sulfasalazine.
Quoted from the “Interactions with Medications” section: NIH Office of Dietary Supplements, health-professional fact sheet, retrieved 2026-11-16. Read the full page for the complete list and references.
FDA adverse-event reports (CAERS)
Matching rule: reports in the dietary-supplement category where a product marked "suspect" has a brand name containing “FOLIC ACID”, “FOLATE”. Products that contain it without naming it are missed. Reports where it was only taken alongside the suspect product are not counted.
Combination products: 69 of the reports involve only products whose name lists another ingredient, such as calcium or a multivitamin. Their reactions may come from that other ingredient or from the tablet itself, so the reactions below count only the 53 reports where a product is named for folate and folic acid alone. This split is made from product names and can misfile some products. Most-reported products: Folic Acid (15); Nature Made Super B-Complex With Vitamin C & Folic Acid (13); Puritan'S Pride Folic Acid 800Mcg Tablets (3); Puritans Pride Folic Acid 800 Mcg Tablets (3); Nature'S Bounty Super B-Complex With Folic Acid Plus Vitamin C (3); Benefiber Fiber Supp Vit B & Folic Acid (3).
| Most reported reactions (single-ingredient products) | Reports |
|---|---|
| Nausea | 7 |
| Vomiting | 5 |
| Dizziness | 5 |
| Diarrhoea | 4 |
| Hypersensitivity | 4 |
| Death | 3 |
| Convulsion | 3 |
| Malaise | 3 |
| Abdominal pain upper | 3 |
| Dyspnoea | 3 |
| Rash | 3 |
| Abdominal pain | 3 |
Outcomes recorded in these reports (a report can have several): Other Serious or Important Medical Event (33), Hospitalization (20), Visited a Health Care Provider (14), Disability (13), Other Serious Outcome (7), Visited Emergency Room (6), Life Threatening (5), Death (3).
Source: openFDA food and supplement adverse events (CAERS), retrieved 2026-11-16.
Registered trials
154 trials in the non-drug evidence map test this class of supplement. Trials with posted results are listed first; each shows the condition it was registered for. A trial testing it in one condition says nothing about another.
- Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder Completed Results posted
- Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer Completed Results posted
- Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEY Completed Results posted
- Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEY Completed Results posted
- A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Completed Results posted
- Exercise Intolerance in Renal Failure Completed Results posted
- Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout Completed Results posted
- Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout Completed Results posted
- Telehealth Delivery (Tele-B6) Completed Results posted
- Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications Completed Results posted
- Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment Completed Results posted
- A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer Completed Results posted
- Phase 2 Trial of Bevacizumab in Combination With Pemetrexed Completed Results posted
- Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC Completed Results posted
- A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer Completed Results posted
- Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Completed Results posted
- Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed Results posted
- Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed Results posted
- A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL Completed Results posted
- GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response Completed Results posted